The prediction of interferon-α therapeutic effect by sequence variation of the HCV hypervariable region 1

Yonsei Medical Journal

Volumn 40, Issue 5, 1999, Pages 430-438

  Yeh, Byung Il ^a   Kim, Hyun Won ^a   Kim, Hyon Suk ^b   Lee, Jong Young ^c   Lee, Kwang Ho ^c   Lee, Kang Mi ^a   Kim, Jin Suk ^b   Han, Kwang Hyub ^b  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Hepatitis C virus; Hypervariable region; Interferon; Quasispecies

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MALE; MOLECULAR CLONING; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032717462     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.1999.40.5.430     Document Type: Article

References (40)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
3. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
4. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-3.
5. Bruix T, Barrera JM, Calvet X. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;ii:1004-6.
6. Colombo M, Kuo G, Choo QL. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;ii:1006-8.
7. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in Southern African blacks with hepatocellular carcinoma. Lancet 1990;335:873-4.
8. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. J Hepatol 1990;12:671-5.
9. Tanaka H, Hiyama T, Tsukuma H, Fujimoto I, Yamano H, Okubo Y, et al. Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical, estimations from cross-sectional data. Jpn J Cancer Res 1994;85:485-90.
10. Gomez RM, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol 1990;11:S63-7.
11. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with IF-α. Hepatology 1992;15:37-41.
12. Takada N, Takase S, Takada A, Date T. Differences in the hepatitis C virus genotypes in different countries. J Hepatol 1993;17:277-83.
13. Tsubota A, Chayama K, Ikeda K, Yasuji A, Loida I, Saitoh S, et al. Factors predictive of response to IFN-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
14. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. J Hepatol 1994;19:871-5.
15. Yoon SK, Kim SS, Park YM, Shim KS, Lee CD, Sun HS, et al. Predictive factors for beneficial response to interferon alfa therapy in chronic hepatitis C. Korean J Intern Med 1995;10:94-102.
16. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino-terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients, Hepatology 1992;16:619-24.
17. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;22:30-5.
18. Yuki N, Hayashi N, Moribe T, Matsushita Y, Tabata T, Inoue T, et al. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology 1997;25:439-44.
19. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-30.
20. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina I, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997;25:750-3.
21. 1 noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J Hepatol 1994;20:623-9.
22. Herion D, Hoofnagle JH. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatology 1997;25:769-71.
23. Frangeul L, Cresta P, Perrin M, Lunel F, Opolon P, Agut H, et al. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Hepatology 1998;28:1674-9.
24. Khorsi H, Stuyver L, Castelain S, Wyseur A, Izopet J, Capron D, et al. Interferon sensitivity determining region (ISDR) in French hepatitis C virus 1b chronically infected patients [abstract]. Hepatology 1996;24:154A.
25. Zeuzem S, Lee JH, Roth WK. Mutations in the non-structural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997;25:740-4.
26. Kato N, Sekiya H, Nakazawa T, Yamauchi K, Ohkoshi S, Gunji T, et al. Hepatitis C virus HVR may confer escape from immunosurveillance. In: Nishioka K, Suzuki H, Mishiro S, Oda T, editors. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag; 1994. p.329-33.
27. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994;20:1144-51.
28. Yeh BI, Han KH, Oh SH, Kim HS, Hong SH, Oh SH, et al. Nucleotide sequence variation in the hypervariable region of the hepaitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy. J Med Virol 1996;49:95-102.
29. Poel van der CL, Cuypers HTM, Reesink HW. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991;337:317-9.
30. Saiki RK, Gelfand DH, Stoffel S, Scharf SV, Higchi R, Horn GT, et al. Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
31. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
32. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 region. J Gen Virol 1993;74:2391-9.
33. Sanger F, Coulson AR. The use of thin acrylamide gels for DNA sequencing. FEES Lett 1978;87:107-10.
34. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-9.
35. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Oh- koshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991;175:220-8.
36. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, et al. Humoral immune response to hypervariable region I of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993;67:3923-30.
37. Davis GL. Recombinant alpha-interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990;11:S72-7.
38. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Frydén A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11:857-62.
39. Piccioto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. J Hepatol 1993;17:359-63.
40. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.